

Ref no: 154051020  
From: Commercial  
Date: 05/10/20  
Subject: Intra-vitreous injections/implants

## REQUEST & RESPONSE

1. Within your trust how many **intra-vitreous injections/implants** of each of the following drugs have been used in the four-month period from May-August 2020:

<b>Aflibercept</b>	<b>98</b>
<b>Bevacizumab</b>	<b>0</b>
<b>Brolucizumab</b>	<b>0</b>
<b>Dexamethasone</b>	<b>14</b>
<b>Fluocinolone</b>	<b>0</b>
<b>Ranibizumab</b>	<b>570</b>

2. If your trust is able to identify **intra-vitreous injections/implants** by eye condition, please provide the number of injections/implants used from May-August 2020, for each of the following conditions:

Wet Age Related Macular Degeneration (wAMD)

Aflibercept  
Becavizumab  
Brolucizumab  
Dexamethasone  
Fluocinolone  
Ranibizumab

Diabetic Macular Oedema (DMO)

Aflibercept  
Becavizumab  
Dexamethasone

Fluocinolone  
Ranibizumab

Retinal Vein Occlusion - Central (CRVO) or Branch (BRVO)

Aflibercept  
Bevacizumab  
Dexamethasone  
Fluocinolone  
Ranibizumab

Visual impairment due to choroidal neovascularization secondary to pathologic myopia (mCNV)

Aflibercept  
Bevacizumab  
Dexamethasone  
Fluocinolone  
Ranibizumab

**St Helens and Knowsley Teaching Hospitals NHS Trust does not hold this information in the requested format.**

3. Within your trust how many patients have been treated for Uveitis in the four-month period from May to August 2020 with the following:

- Dexamethasone intra-vitreal implants
- Any other anti-VEGF injections/implants
- Infliximab
- Adalimumab
- Tocilizumab

**St Helens and Knowsley Teaching Hospitals NHS Trust does not hold this information in the requested format.**